Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences T.PMN

Alternate Symbol(s):  ARFXD

ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It primarily operates in Canada.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 
@ the Bell: U.S. markets decline amid new inflation numbers
American investors sold off in the equity market Friday, after the U.S. Department of Commerce released new numbers showing the rate of inflation is outpacing predictions. The three major American... read article.

RE:New ceo

Fantastic RC, so what progressive initiative do you see her bringing before the first P1 results?   rate and reply

Luff Enterprises National E-Commerce Platform Now Live

LUFF has engaged over 50 licensed producers as potential suppliers with over 30 of them qualified as approved vendors with 127 SKUs approved for sale on the marketplace. It is expected that another 10 vendors and 170 SKUs will be added to the site in the coming weeks making Herbal Dispatch already one of the largest purveyors of medical cannabis products in Canada. more

New ceo

Had a chance recently to meet the new ceo.  Pretty darn impressed with this lady considering she has only been on the job for 4 days.  . The best way to describe her is a realistic more
The Market Herald’s Weekly Cannabis Report – Sept 30, 2022
Fire & Flower (TSX:FAF) has launched a co-located store with Circle K in Brampton, Ontario. The store showcases a convenience cannabis store model expanding on Circle K’s offerings, including... read article.

RE:RE:RE:RE:RE:RE:biogen suffering ?

The difference with PMN310 has always been there. Targetting toxic oligomers. It can't be clearer than that. ProMIS has always made that very plain. Selectivity! The jury is still out more

RE:313% upside?

Darn, everytime these guys say this the price goes down and they have repeated this. Keeping  friendly ties for PP's.  rate and reply

313% upside? "Leede Jones Gable analyst Douglas Loe provided an update on Wednesday on more

RE:RE:RE:RE:RE:biogen suffering ?

I hope she leverages the modest benefit of lecanemab into a promotional strategy that stresses PMN310s differences rather than similarities. It's almost October, the baseball analogies more

RE:RE:RE:RE:biogen suffering ?

What is there to leverage? Aducanumab is an expensive, lacklustre drug! G1945V  rate and reply

RE:RE:RE:biogen suffering ?

It's the sort of good but not too good news our consultants were hoping for when they hyped Aducanumab. I hope the new CEO leverages it more strategically this time, doesn't seem like more
Buzz on the Bullboards: Laying plans
It’s been a busy week for the markets, which means a busy week for the Bullboards. From new sector mainstays to sudden investment opportunities, we saw a bit of everything over the last week.On... read article.

RE:RE:biogen suffering ?

I would say this Biogen news might gety our genertors turning again and get some eyes in here........We do need it..  rate and reply

RE:biogen suffering ?

Exactly my point RC, cost of doing business.  I would call these guys corrupt except there is no such thing in the oligopoly.  It's like calling Crooks in Action corrupt, it's just more

RE:biogen suffering ?

Sept 28 (Reuters) - Biogen Inc (BIIB.O) was set to add more than $10 billion to its market capitalization on Wednesday, as a surprise trial success of the experimental Alzheimer's more

biogen suffering ?

Yes looks like the MS settlement hit  them pretty hard today.. a hate to see what happens when some good news comes out   $270.8073.005 | 36.91%Bid: 270.60 more

RE:Alzheimer’s Progression Slowed by Drug in Major Trial

LOL, cost of today's announcement: $US 900 million, a bargain! more

Uk view of announcement

Success of experimental Alzheimer’s drug hailed as ‘historic moment’ Study shows cognition in early-stage patients on lecanemab declines by 27% less than those on placebo Hannah more

RE:Alzheimer’s Progression Slowed by Drug in Major Trial

"The company said results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with more

Alzheimer’s Progression Slowed by Drug in Major Trial   Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug lecanemab slowed the disease, becoming the first medicine to clearly blunt more

old news but cool

this was probably already posted, but I just saw it for the first time and thought it was cool  rate and reply

RE:Boston Private Placement

[/quote Wrong .. u r   rate and reply

Boston Private Placement

Folks, brace yourself for another BIG PP coming. The IND work for filing is just a distraction probably done already but they will hold until the last moment for obvious  placement reasons? more

Obesity and alzhiemers treatment domain focus  rate and reply